Global Brain has invested in Craif Inc. (Craif), an exosome-based liquid biopsy company that develops innovative non-invasive urinary liquid biopsy for early detection of cancer, through its KIRIN HEALTH INNOVATION FUND.
Craif is a startup from Nagoya University and has developed a liquid biopsy-based biomarker research platform with a distinctive technology to capture urinary microRNA effectively and combining it with AI (artificial intelligence) for medical and healthcare fields. Craif is working to solve issues of cancer treatment by implementation of highly accurate urinary test for early-stage cancer.
As the population is aging, the number of cancer patients is also on the rise. Unlike conventional blood tests, Craif uses a unique technology that comprehensively captures microRNA from urine, enabling highly accurate early detection of cancer in a way that is not a burden on patients. In addition, microRNA has recently gotten attention as a biomarker of diseases other than cancer and has potential to be applied to healthcare and drug development.
Global Brain has decided to invest in Craif because of the potential of talented management with strong R&D capability, great opportunity of early cancer detection market, and scalability of the product to health science area. Global Brain will contribute to the business growth of Craif in collaboration with Kirin Holdings.
About Craif
- Location
- Bunkyo-ku, Tokyo, Japan
- Representative
- Ryuichi Onose
- Founded
- May 2018
About KIRIN HEALTH INNOVATION FUND
- Name
- KIRIN-GB Fund I L.P.
- Fund Term
- 10 years
- Fund Size
- JPY 5 billion
- General Partner
- Global Brain Corporation
About Global Brain
- Location
- Tokyo, Japan
- Representative
- Yasuhiko Yurimoto
- Founded
- January 1998